CA2985637A1 - Autoantigens for diagnosis of rheumatoid arthritis - Google Patents

Autoantigens for diagnosis of rheumatoid arthritis

Info

Publication number
CA2985637A1
CA2985637A1 CA2985637A CA2985637A CA2985637A1 CA 2985637 A1 CA2985637 A1 CA 2985637A1 CA 2985637 A CA2985637 A CA 2985637A CA 2985637 A CA2985637 A CA 2985637A CA 2985637 A1 CA2985637 A1 CA 2985637A1
Authority
CA
Canada
Prior art keywords
filamin
subject
sulfatase
acetylglucosamine
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2985637A
Other languages
English (en)
French (fr)
Inventor
Allen C. Steere
Elise E. DROUIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CA2985637A1 publication Critical patent/CA2985637A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2985637A 2015-05-12 2016-05-12 Autoantigens for diagnosis of rheumatoid arthritis Abandoned CA2985637A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562160320P 2015-05-12 2015-05-12
US62/160,320 2015-05-12
US201562162295P 2015-05-15 2015-05-15
US62/162,295 2015-05-15
PCT/US2016/032077 WO2016183310A1 (en) 2015-05-12 2016-05-12 Autoantigens for diagnosis of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CA2985637A1 true CA2985637A1 (en) 2016-11-17

Family

ID=57248470

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985637A Abandoned CA2985637A1 (en) 2015-05-12 2016-05-12 Autoantigens for diagnosis of rheumatoid arthritis

Country Status (6)

Country Link
US (1) US10429379B2 (enExample)
EP (1) EP3294901B1 (enExample)
JP (1) JP6663000B2 (enExample)
AU (1) AU2016261939A1 (enExample)
CA (1) CA2985637A1 (enExample)
WO (1) WO2016183310A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10908159B2 (en) 2016-06-07 2021-02-02 The General Hospital Corporation Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with Rheumatoid arthritis
US20180280503A1 (en) 2017-04-04 2018-10-04 The Johns Hopkins University Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
JP7202010B2 (ja) * 2017-07-06 2023-01-11 国立大学法人 筑波大学 関節リウマチ診断薬
US20210388345A1 (en) * 2018-10-22 2021-12-16 Roche Sequencing Solutions, Inc. Profiling of rheumatoid arthritis autoantibody repertoire and peptide classifiers therefor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1105734B (it) * 1977-07-14 1985-11-04 Syva Co Prova di legame di competizione di antienzima omogeneo
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5248595A (en) 1991-10-08 1993-09-28 Eastman Kodak Company Wash composition, test kit and method for determination of microorganisms associated with periodontal diseases
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
AU2002230997A1 (en) 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20050130117A1 (en) * 2001-10-03 2005-06-16 Davis Cong L. Modulators of lymphocyte activation and migration
US9493539B2 (en) 2003-03-07 2016-11-15 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
DE602004030586D1 (de) 2003-09-15 2011-01-27 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
WO2005064307A2 (en) 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
ES2314621T3 (es) 2004-02-27 2009-03-16 F. Hoffmann-La Roche Ag Procedimiento de evaluacion de la artritis reumotoidea, mediante la medicion de anti-ccp y amiloide a serico.
WO2006008183A1 (en) 2004-07-23 2006-01-26 Novartis Ag Biomarkers for rheumatoid arthritis (ra)
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
IN2012DN02485A (enExample) 2009-09-03 2015-08-28 Hoffmann La Roche
WO2012040264A2 (en) * 2010-09-21 2012-03-29 The General Hospital Corporation Diagnostic tests for immune reactivity with human endothelial cell growth factor
AU2011372528C1 (en) * 2011-07-01 2017-01-19 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
KR20160014584A (ko) * 2013-03-13 2016-02-11 코어 파마슈티칼스 디벨롭먼트 컴퍼니 염증 치료용 면역-변형된 입자
US10908159B2 (en) 2016-06-07 2021-02-02 The General Hospital Corporation Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with Rheumatoid arthritis

Also Published As

Publication number Publication date
JP6663000B2 (ja) 2020-03-11
AU2016261939A1 (en) 2018-01-04
EP3294901A1 (en) 2018-03-21
JP2018517151A (ja) 2018-06-28
US20180156778A1 (en) 2018-06-07
US10429379B2 (en) 2019-10-01
EP3294901B1 (en) 2023-05-03
WO2016183310A1 (en) 2016-11-17
EP3294901A4 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
Sokolova et al. Autoantibodies in rheumatoid arthritis: historical background and novel findings
Volkov et al. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology
Wang et al. Immunogenic HLA-DR-presented self-peptides identified directly from clinical samples of synovial tissue, synovial fluid, or peripheral blood in patients with rheumatoid arthritis or lyme arthritis
Harre et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
Feitsma et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA–DR4–positive patients with rheumatoid arthritis
JP5998318B2 (ja) 新規血管炎の検査方法および検査用試薬
CN102576022A (zh) 诊断和治疗自闭症的方法
Trier et al. Anti-citrullinated protein antibodies as biomarkers in rheumatoid arthritis
US10429379B2 (en) Autoantigens for diagnosis of rheumatoid arthritis
Lepper et al. Proteomic landscape of patient-derived CD4+ T cells in recent-onset type 1 diabetes
Cantagrel et al. New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified self-proteins
Goto et al. Identification of cerebral infarction-specific antibody markers from autoantibodies detected in patients with systemic lupus erythematosus
Routsias et al. Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response
KR20210041559A (ko) 다발경화증에서의 면역우세 단백질 및 단편
US11982671B2 (en) Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with rheumatoid arthritis
Chen et al. Identification of heat shock protein 27 as a novel autoantigen of Behçet’s disease
WO2016003719A1 (en) Autoantigens for diagnosis of chronic inflammatory diseases
Bridges Jr Update on autoantibodies in rheumatoid arthritis
US20130302329A1 (en) Diagnostic tests for immune reactivity with human endothelial cell growth factor
JP6536944B2 (ja) 自己免疫疾患の発症に関与する細胞を判定する方法及びその利用
US20180313830A1 (en) Peptide and biomarker associated with inflammatory disorders, and uses thereof
Thomas The unexpected localization of PAD4 in monocytes: implications for rheumatoid arthritis pathogenesis
Meroni et al. Antiphospholipid and antiendothelial antibodies
JP2012224594A (ja) 環状シトルリン化グルコース−６−リン酸イソメラーゼペプチドおよび関節リウマチ症診断方法
Tutturen Enrichment and identification of citrullinated proteins in biological samples

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220803

FZDE Discontinued

Effective date: 20220803